CLAIMS

Claim 1 (original): A pharmaceutical composition for treatment of malignancies which comprises in combination a bisphosphonate and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use.

Claim 2 (original): Use of an HMG-CoA reductase inhibitor for the preparation of a medicament, for use in combination with a bisphosphonate for treatment of a malignant disease.

Claim 3 (original): Use of a bisphosphonate for the preparation of a medicament for use in combination with an HMG-CoA reductase inhibitor for treatment of a malignant disease.

Claim 4 (original): Use of an HMG-CoA reductase inhibitor in combination with a bisphosphonate to inhibit cancer cell growth or induce cancer cell apoptosis.

Claim 5 (original): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of a bisphosphonate and an effective amount of an HMG-CoA reductase inhibitor.

Claim 6 (currently amended): A composition according to claim 1, ~~use according to claims 2-4, or method according to claim 5~~ for the inhibition of cancer cell growth or induction cancer cell apoptosis.

Claim 7 (currently amended): A composition according to claim 1, ~~use according to claims 2-4, or method according to claim 5,~~ in which the bisphosphonate is an N-bisphosphonate.

Claim 8 (currently amended): A composition according to claim 1, ~~use according to claims 2-4, or method according to claim 5,~~ in which the bisphosphonate is a compound of formula I



I

wherein

X is hydrogen, hydroxyl, amino, alkanoyl,or an amino group substituted by C_1-C_4 alkyl, or alkanoyl;

R is hydrogen or C_1-C_4 alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles),

or a pharmaceutically acceptable salt thereof or any hydrate thereof.

Claim 9 (currently amended): A composition according to claim 1, ~~use according to claims 2-4, or method according to claim 5,~~ in which the bisphosphonate is 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 10 (original): A method of treating a patient suffering from a malignant disease comprising administering to the patient an effective amount of an HMG-CoA reductase inhibitor.

Claim 11 (currently amended): A method according to ~~claim 5 or~~ claim 10, in which the HMG-CoA reductase inhibitor is a statin.

Claim 12 (original): A method according to claim 11, in which the HMG-CoA reductase inhibitor is fluvastain or a pharmaceutically acceptable salt of ester thereof.

Claim 13 (new): The method according to claim 5, in which the bisphosphonate is 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmacologically acceptable salt thereof.

Claim 14 (new): The method according to claim 5 for the inhibition of cancer cell growth or induction cancer cell apoptosis.

Claim 15 (new): The method according to claim 5 in which the bisphosphonate is an N-bisphosphonate.

Claim 16 (new): The method according to claim 5 in which the bisphosphonate is a compound of formula I



I

wherein

X is hydrogen, hydroxyl, amino, alkanoyl,or an amino group substituted by C_1-C_4 alkyl, or alkanoyl;

R is hydrogen or C_1-C_4 alkyl and

Rx is a side chain which contains an optionally substituted amino group, or a nitrogen containing heterocycle (including aromatic nitrogen-containing heterocycles),

or a pharmaceutically acceptable salt thereof or any hydrate thereof.